Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Other hematologic neoplasm 1Myeloid 1Breast 1

Conditions

Prostatic Neoplasms 502Urinary Bladder Neoplasms 139Carcinoma, Renal Cell 116Neoplasms 66Kidney Neoplasms 53Non-Muscle Invasive Bladder Neoplasms 43Neoplasm Metastasis 38Carcinoma, Transitional Cell 38Breast Neoplasms 30Testicular Neoplasms 28Recurrence 20Wilms Tumor 18Parkinson Disease 4, Autosomal Dominant Lewy Body 14Pain 13Ovarian Neoplasms 13Urologic Neoplasms 12Testicular Germ Cell Tumor 12Teratoma 12Seminoma 12Multiple Myeloma 12Burkitt Lymphoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Carcinoma, Ovarian Epithelial 11Carcinoma 11Urogenital Neoplasms 10Neuroblastoma 10Lymphoma, Non-Hodgkin 10Lymphoma, Mantle-Cell 10Lymphoma, Large-Cell, Immunoblastic 10

Interventions

pazopanib 1enzalutamide 1apalutamide 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Patient Preference × Genitourinary × Clear all
NCT04409288 2024-01-05

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

Chinese University of Hong Kong

Phase 3 Terminated
74 enrolled
Genitourinary

Prostatic Neoplasms, Patient Preference

NCT01064310 2017-04-17

PISCES

Novartis

Phase 3 Completed
169 enrolled 16 charts
Genitourinary

Carcinoma, Renal Cell, Neoplasms, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon âš¡